Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.5% – Should You Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price was up 2.5% during mid-day trading on Tuesday . The stock traded as high as $1,177.58 and last traded at $1,175.15. 2,076,317 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 3,165,183 shares. The stock had previously closed at $1,146.90.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Negative Sentiment: Novo Nordisk claims Lilly used outdated clinical trial data in ads that compared Zepbound and Mounjaro against Wegovy and Ozempic, potentially overstating Lilly’s effectiveness and risking regulatory, legal, and reputational fallout. Reuters: Novo Nordisk says it is suing Eli Lilly, accusing it of false advertising
• Negative Sentiment: The complaint seeks to stop the advertising and recover damages, which could add uncertainty around a key growth franchise in Lilly’s fast-growing obesity market. CNBC: Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
• Neutral Sentiment: Despite the lawsuit, broader investor attention remains on Lilly’s strong fundamentals and leadership in obesity drugs, with analysts still pointing to its growth outlook and expanding pipeline as longer-term supports. Zacks: GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

Analysts Set New Price Targets

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald lifted their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a research note on Monday, July 6th. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Leerink Partners raised their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Finally, Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company Trading Up 2.5%

The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a 50-day simple moving average of $1,122.49 and a two-hundred day simple moving average of $1,036.98. The firm has a market capitalization of $1.11 trillion, a P/E ratio of 41.75, a price-to-earnings-growth ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 34.55 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Basso Capital Management L.P. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $30,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after purchasing an additional 24 shares in the last quarter. Finally, Dorato Capital Management purchased a new stake in Eli Lilly and Company during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.